Finance

Lists
QNCX:NASDAQ
Quince Therapeutics Inc
US$31,73
0,00%
(0,00) 1D
9 ຕ.ລ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QNCX...
Mkt. cap
32,27 ລ້ານ
Avg. vol.
22,66 ພັນ
Volume
0,00
52-wk high
US$909,98
52-wk low
US$15,10
EPS
US$-125,71
Beta
1,33
Shares outstanding
1,02 ລ້ານ
No. of employees
38
Mkt. cap
32,27 ລ້ານ
Avg. vol.
22,66 ພັນ
Volume
0,00
52-wk high
US$909,98
52-wk low
US$15,10
EPS
US$-125,71
Beta
1,33
Shares outstanding
1,02 ລ້ານ
No. of employees
38
News stories
From web sources and news partners
About Quince Therapeutics Inc
CEO-
Employees38
Founded2012
HeadquartersSouth San Francisco, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Analyst ratings
Based on 8 analysts giving stock ratings to QNCX in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for QNCX in the last 3 months.
Highest
Current US$31,73
US$98,00 (+208,86%)
Average
US$75,63 (+138,35%)
Lowest
US$68,00 (+114,31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tiago Fauth
Raymond James
Buy
Initiated
US$72,00
+126,9%
10/09/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
US$98,00
+208,9%
09/30/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
US$68,00
+114,3%
09/29/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
US$68,00
+114,3%
09/30/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
US$70,00
+120,6%
09/24/2026
Jonathan Wolleben
Citizens JMP
Buy
Upgraded
US$77,00
+142,7%
09/22/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Reiterated
US$70,00
+120,6%
08/17/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
US$82,00
+158,4%
08/17/2026
Jason McCarthy
Maxim Group
Hold
Downgraded
-
-
02/02/2026
Elemer Piros
Lucid Capital
Sell
Downgraded
-
-
01/30/2026
Jason Kolbert
D. Boral Capital
Hold
Downgraded
-
-
01/30/2026
Last report
14 ສ.ຫ. 2026
Fiscal period
Q2 2026
US$-12,15 / US$-12,39
+1,88%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8,08 ລ້ານ
12,60 ລ້ານ
6,84 ລ້ານ
5,46 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,28 ລ້ານ
3,64 ລ້ານ
4,27 ລ້ານ
16,63 ລ້ານ
Operating expense
11,36 ລ້ານ
16,24 ລ້ານ
11,11 ລ້ານ
22,09 ລ້ານ
Total operating expenses
11,36 ລ້ານ
16,24 ລ້ານ
11,11 ລ້ານ
22,09 ລ້ານ
Operating income
-11,36 ລ້ານ
-16,24 ລ້ານ
-11,11 ລ້ານ
-22,09 ລ້ານ
Other non operating income
191,00 ພັນ
-17,12 ລ້ານ
32,84 ລ້ານ
3,78 ລ້ານ
EBT including unusual items
-13,49 ລ້ານ
-36,31 ລ້ານ
30,57 ລ້ານ
-75,41 ລ້ານ
EBT excluding unusual items
-10,87 ລ້ານ
-32,65 ລ້ານ
21,88 ລ້ານ
-17,72 ລ້ານ
Income tax expense
-46,00 ພັນ
3,15 ລ້ານ
-5,34 ລ້ານ
75,00 ພັນ
Effective tax rate
0,34%
-8,66%
-17,46%
-0,10%
Other operating expenses
-
-
-
-
Net income
-13,44 ລ້ານ
-39,46 ລ້ານ
35,91 ລ້ານ
-75,49 ລ້ານ
Net profit margin
-
-
-
-
Earnings per share
-50,00
-152,00
57,60
-12,15
Interest and investment income
300,00 ພັນ
227,00 ພັນ
160,00 ພັນ
584,00 ພັນ
Interest expense
-
-
-
-
Net interest expenses
300,00 ພັນ
227,00 ພັນ
160,00 ພັນ
584,00 ພັນ
Depreciation and amortization charges
-
-
-
-
EBITDA
-11,33 ລ້ານ
-16,20 ລ້ານ
-11,08 ລ້ານ
-22,05 ລ້ານ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
ແອັບຂອງ Google